Infectious Diseases

The ACIP committee voted to pass both resolutions to update its recommendation on the hepatitis B vaccine for infants.

"For those not receiving the HBV birth dose, it is suggested that the initial dose is administered no earlier than 2 months of age," reads part of vote 1.

New US modeling study results find nirsevimab would avert the most infant RSV-LRTD events and hospitalizations compared with clesrovimab or RSVpreF maternal vaccination.

A national poll shows many parents plan in-person Thanksgiving gatherings despite concerns about COVID-19 transmission and risks to high-risk relatives.

The CDC website now claims "studies supporting a link [between vaccines and autism] have been ignored by health authorities."

The American Academy of Pediatrics updates guidelines, allowing doxycycline use in young children for tick-borne infections, enhancing treatment options.

Ruth Lynfield, MD, discusses an approach clinicians can take in counseling parents who may have concerns about vaccines.

Anne Kasmar, MD, MSc, highlighted how AMR innovation relies on immune-based science, novel modalities, and strong regulatory collaboration at IDWeek 2025.

In this Q&A, nurse practitioner Tracey Gaslin, PhD, discusses tick bites in pediatric patients, from how to prevent a bite to what to do after a bite, and highlights resources available from the Fight the Bite initiative.

Key highlights from the conference included public health, advocacy for vaccines, and artificial intelligence.

Zoliflodacin study investigator Sarah McLeod, PhD, highlights data presented at IDWeek 2025 in this Q&A with Contemporary Pediatrics.

In this brief clip, Lori Handy, MD, MSCE, of CHOP, explains the evolving dynamic of trust between patients, parents, and health care.

Lori Handy, MD, MSCE, discussed how clinicians can strengthen vaccine communication by engaging openly and partnering with trusted community messengers.

Nicholas P. Marshall, MD, FAAP, discussed how generative AI can help streamline infectious disease workflows and enhance evidence-based care at IDWeek 2025 in Atlanta.

Yohei Doi, MD, IDWeek chair, Infectious Diseases Society of America, provides some insights on the happenings at this year’s event from Atlanta, Georgia.

* Generic lenacapavir could be produced for $25 per person per year at scale, according to an analysis presented at IDWeek 2025 in Atlanta.

Combined or individual use of maternal RSVpreF and infant nirsevimab achieved high antibody levels without safety concerns, supporting current RSV prevention strategies.

IDWeek 2025 heads to Atlanta October 19–22 with cutting-edge sessions on AMR, AI, vaccines, HIV, pediatrics, and global health challenges.

IDSA’s new GAS pharyngitis guidance emphasizes selective testing using clinical scoring to reduce overtreatment and antibiotic misuse.

Lori Handy, MD, MSCE, addresses rising vaccine inquiries, emphasizing informed decisions that balance risks and benefits for children's health and safety.

Combination vaccines enhance childhood immunization by reducing the number of shots, improving adherence, and potentially increasing overall vaccination rates.

C. Buddy Creech, MD, MPH, highlights advances in mRNA, monoclonals, adjuvants, and mucosal vaccines, stressing safety and parent communication.

Pediatric flu deaths underscore risks for healthy children and highlight importance of annual vaccination and early recognition.